Long-Read Cost Compression And Slower Clinical Adoption Will Pressure Long-Term Business Fundamentals

Catalysts

About Pacific Biosciences of California

Pacific Biosciences of California develops and sells long read and high accuracy sequencing platforms, chemistries and workflows used in genomic and epigenomic research and emerging clinical applications.

What are the underlying business or industry changes driving this perspective?

• The effort to make long read genomes cost competitive with short read platforms through SPRQ Nx and multi use SMRT Cells could commoditize PacBio's key differentiation. This could force sustained price cuts that limit revenue growth even as volumes rise and could cap gross margin expansion.
• As clinical genomics and large population programs scale, competing long read and improved short read technologies may capture a disproportionate share of new projects. This could leave PacBio with slower instrument placements and consumables pull through and could pressure top line growth assumptions.
• If academic and government funding in the Americas and Asia Pacific remains structurally constrained while clinical adoption ramps more slowly than expected, PacBio's installed base growth could lag expectations. This could limit recurring consumable revenue and delay the path to positive earnings.
• Expanding into complex clinical assays such as carrier screening, rare disease and oncology exposes PacBio to longer validation cycles, reimbursement uncertainties and higher support needs. These factors can inflate operating expenses faster than revenue and constrain net margin improvement.
• Large population scale initiatives in aging, national reference genomes and broad precision medicine cohorts may take longer to contract and ramp than anticipated. This may create gaps in expected high throughput utilization that undercut projected revenue leverage and delay operating breakeven.

Assumptions

This narrative explores a more pessimistic perspective on Pacific Biosciences of California compared to the consensus, based on a Fair Value that aligns with the bearish cohort of analysts. How have these above catalysts been quantified?

• The bearish analysts are assuming Pacific Biosciences of California's revenue will grow by 9.1% annually over the next 3 years.
• The bearish analysts are not forecasting that Pacific Biosciences of California will become profitable in next 3 years. To represent the Analyst Price Target as a Future PE Valuation we will estimate Pacific Biosciences of California's profit margin will increase from -325.8% to the average US Life Sciences industry of 15.5% in 3 years.
• If Pacific Biosciences of California's profit margin were to converge on the industry average, you could expect earnings to reach $31.2 million (and earnings per share of $0.1) by about December 2028, up from $-503.6 million today.
• In order for the above numbers to justify the price target of the more bearish analyst cohort, the company would need to trade at a PE ratio of 20.1x on those 2028 earnings, up from -1.3x today. This future PE is lower than the current PE for the US Life Sciences industry at 34.6x.
• The bearish analysts expect the number of shares outstanding to grow by 1.36% per year for the next 3 years.
• To value all of this in today's terms, we will use a discount rate of 9.99%, as per the Simply Wall St company report.

Risks

What could happen that would invalidate this narrative?

• Record and growing consumables usage, including a 15% year over year increase to an all-time high and Revio pull-through near the top of its guided range, suggests a durable, recurring demand base that can compound revenue and support improving gross margins over time.
• The shift of the installed base and sales funnel toward clinical and commercial customers, alongside early regulatory wins such as the first clinical-grade long-read approval in China and expanding clinical assays like carrier screening and rare disease, points to structurally more resilient end markets that can accelerate revenue growth and drive margin expansion.
• Large population genomics initiatives and national reference projects that have already selected PacBio HiFi as a primary platform, including aging studies and pangenome efforts, create multi-year, high-volume sequencing pipelines that can add incremental revenue and enhance earnings power once they scale.
• The SPRQ Nx chemistry and multi use SMRT Cells are designed to cut long-read genome costs to roughly short-read levels while simultaneously lifting consumable gross margins, a combination that could materially expand PacBio’s addressable market and improve net margins faster than currently assumed.
• Ongoing restructuring, lower headcount and disciplined operating expense management are already reducing annual cash burn by more than $70 million, and management’s path to cash flow breakeven exiting 2027 indicates improving operating leverage that could support higher future earnings than implied by a bearish share price outlook.

Valuation

How have all the factors above been brought together to estimate a fair value?

• The assumed bearish price target for Pacific Biosciences of California is $1.5, which represents up to two standard deviations below the consensus price target of $2.29. This valuation is based on what can be assumed as the expectations of Pacific Biosciences of California's future earnings growth, profit margins and other risk factors from analysts on the more bearish end of the spectrum.
  
• However, there is a degree of disagreement amongst analysts, with the most bullish reporting a price target of $3.0, and the most bearish reporting a price target of just $1.5.
  
• In order for you to agree with the more bearish analyst cohort, you'd need to believe that by 2028, revenues will be $200.9 million, earnings will come to $31.2 million, and it would be trading on a PE ratio of 20.1x, assuming you use a discount rate of 10.0%.
  
• Given the current share price of $2.17, the analyst price target of $1.5 is 44.7% lower. Despite analysts expecting the underlying business to improve, they seem to believe the market's expectations are too high.
  
• We always encourage you to reach your own conclusions though. So sense check these analyst numbers against your own assumptions and expectations based on your understanding of the business and what you believe is probable.